We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

55 hedge funds and large institutions have $168M invested in NKGen Biotech, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $155M → $168M (+$12.7M)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

7% less funds holding

Funds holding: 59 → 55 (-4)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
8
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$8.14M
2
PC
Periscope Capital
Ontario, Canada
+$4.6M
3
UOC
UBS O'Connor
Illinois
+$3.23M
4
KL
KIM LLC
Kansas
+$3.03M
5
KIM
Karpus Investment Management
New York
+$2.95M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$5.87M
2
CAC
Cowen and Company
New York
-$3.62M
3
TCA
Taconic Capital Advisors
New York
-$3.48M
4
JP Morgan Chase
JP Morgan Chase
New York
-$2.37M
5
EC
Elequin Capital
New York
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
51
Robinson Capital Management
Michigan
$122K – – –
LCM
52
Landscape Capital Management
New Jersey
$115K – – –
DFCM
53
Dark Forest Capital Management
Puerto Rico
$38.7K – – –
SFM
54
Spartan Fund Management
Canada
$14.2K +$14.1K +1,400 New
UBS Group
55
UBS Group
Switzerland
$5.98K -$11.6K -1,150 -66%
Marshall Wace
56
Marshall Wace
United Kingdom
– -$5.87M -589,724 Closed
CAC
57
Cowen and Company
New York
– -$3.62M -363,598 Closed
TCA
58
Taconic Capital Advisors
New York
– -$3.48M -350,000 Closed
EC
59
Elequin Capital
New York
– -$2.18M -218,800 Closed
CM
60
Crestline Management
Texas
– -$756K -76,000 Closed
CL
61
CSS LLC
Illinois
– -$525K -52,753 Closed
Susquehanna International Group
62
Susquehanna International Group
Pennsylvania
– -$245K -24,593 Closed
VF
63
Virtu Financial
New York
– -$243K -24,401 Closed
CIM
64
Corbyn Investment Management
Maryland
– -$113K -11,320 Closed
CS
65
Clear Street
New York
– -$7K -700 Closed
1 2
3

NKGN Hedge Fund Activity: Q1 2023 in Review

55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2023, worth a combined $168M — up 8.2% from $155M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NKGN and 7 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $8.14M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.87M sold.

  • 55 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2023, down from 59 in Q4 2022.
  • Funds reported $168M of NKGen Biotech, Inc. Common Stock stock for Q1 2023, up 8.2% quarter-over-quarter.
  • 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -3 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2023 was Aristeia Capital, an estimated $8.14M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q1 2023 was Marshall Wace, an estimated $5.87M sold.

Based on aggregated 13F filings for Q1 2023.